Key trends and challenges are shaping the next era of advanced therapies, from FDA momentum to broader patient access.

Fran Gregory, PharmD, MBA, VP of emerging therapies at Cardinal Health, talks about the importance of market access strategies in the cell and gene therapy space.

L7 Informatics’ Marcia Blackmoore on how structured data, digital workflows, and real-time orchestration are helping CDMOs deliver at scale without compromising quality.

Non-coding RNAs (ncRNAs), once considered the 'dark matter' of the genome, have now emerged as pivotal regulators in cancer ...